ERBB2 and breast cancer: Nevertheless, these data indicate that HR status has a crucial role among patients with HER2-low breast cancer, and this indication is in line with the different response rates of novel anti-HER2 antibody–drug conjugates for HER2-low breast cancer according to the HR status [8, 10].